General Information of This Drug (ID: DMDLJM1)

Drug Name
NKR-2 CAR-T Cells   DMDLJM1
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2